NDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
2
Data completeness
2/8 — Basic
ABACAVIR SULFATE (abacavir sulfate) by Matrix Surgical USA is 12.
Drug data last refreshed 8h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Abacavir sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral agent used to treat HIV infection. It works by inhibiting reverse transcriptase, an enzyme essential for HIV replication. The drug is rapidly absorbed orally with 83% bioavailability and is suitable for both tablet and oral solution formulations.
Pre-Launch
Pre-launch stage suggests limited current commercial infrastructure; career opportunities tied to launch readiness in a mature HIV market dominated by combination therapies.
Mechanism of Action
12.1 Mechanism of Action Abacavir is an antiretroviral agent [see ]. 12.3 Pharmacokinetics Pharmacokinetics in Adults The pharmacokinetic properties of abacavir were independent of dose over the range of 300 to 1,200 mg per day. Absorption Following oral administration, abacavir is rapidly absorbed…
Worked on ABACAVIR SULFATE at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.